Aug 26, 2026 10:00 PM

San Francisco Giants shortstop Willy Adames has been diagnosed with a sprained UCL in his left elbow.

The San Francisco Giants are facing uncertainty surrounding Willy Adames after the veteran shortstop was diagnosed with a sprained ulnar collateral ligament in his left elbow.

Adames was placed on the Injured List Monday after suffering the injury during a slide at home plate. Because the affected elbow is on his non-throwing arm, the Giants have not yet determined whether surgery will be necessary.

That leaves Adames' status for the remainder of the season unclear as San Francisco evaluates the best path forward.

The injury comes at an especially unfortunate point for Adames, who had begun to show signs of improvement after a difficult opening stretch to the season. While his overall numbers remain below the level the Giants likely expected when they signed him, his production had been trending in a more positive direction over the past several months.

Adames is in the second season of a seven-year, $182 million contract with San Francisco. His first year with the Giants provided a mixture of power and defensive production as he finished with 30 home runs while remaining an important presence at shortstop.

His second season has been more uneven.

Adames has already hit 21 home runs, continuing to provide the power that has been a defining part of his offensive profile. However, his on-base production has declined, while his strikeout rate has risen slightly. His defensive performance has also taken a step backward compared with his first season in San Francisco.

Still, the recent trend at the plate offered some encouragement.

After struggling considerably during the opening month, Adames settled into a better offensive rhythm beginning in May. He has produced a stronger overall batting line since that point, while his walk rate has gradually improved as the season has progressed.

That development makes the timing of the injury particularly frustrating for the Giants.

Rather than continuing to build on that progress, Adames will now have to focus on recovering from the elbow issue. Since the injury involves his non-throwing arm, there remains a possibility that rehabilitation could allow him to avoid a more serious surgical procedure. The organization will have to determine the next steps after further evaluation.

Adames' absence also creates another challenge for a Giants club dealing with several injuries throughout the roster.

San Francisco has already lost left-hander Carson Whisenhunt to a significant UCL injury, with surgery expected to keep the young pitcher out for an extended period. The Giants also received another concerning injury development involving Adrian Houser.

Houser exited his start Tuesday after only 1.2 innings and is scheduled to undergo an MRI. He had recently returned to the rotation after spending time working in long relief and had been one of the Giants' more effective pitchers during that stretch.

While Houser's diagnosis remains unknown, his injury adds another question mark to a team that is already navigating significant health concerns.

For the Giants, however, Adames represents a different kind of concern. His importance extends beyond the immediate lineup because of the long-term commitment the organization made to him.

San Francisco signed Adames to provide stability at shortstop while adding power to the middle of the lineup. An extended absence would leave the Giants without one of their most experienced infielders during the final portion of the season.

The Giants will have to wait for additional evaluations before determining how long Adames could be sidelined. For now, the primary objective is getting him healthy while determining whether rehabilitation alone can resolve the UCL sprain.

With his offensive production beginning to trend upward, the timing of the injury could not be more frustrating for Adames and the Giants.

Comments
anonymous profile image
Powered by RoundtableBuilt on infrastructure designed for real-time media. Learn more at RTB.io.© Roundtable 2026. By using this site you agree to the Terms of Use and Privacy Policy